Mood modification with raloxifene and continuous combined estrogen plus progestin hormone therapy

International Journal of Fertility and Women's Medicine

Volumn 49, Issue 3, 2004, Pages 120-122

  Carranza Lira, Sebastián ^a,c   MacGregor Gooch, Ana Luz ^a   Saráchaga Osterwalder, Max ^b  

^a Gynecology and Obstetrics Hospital   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c NONE   (Mexico)

Author keywords

Depressive mood; Estrogen plus progestin therapy; Hamilton Depression Rating Scale; Raloxifene

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; RALOXIFENE; ANTIESTROGEN; MEDROXYPROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGE; ANTHROPOMETRY; ARTICLE; CLIMACTERIUM; CLINICAL ARTICLE; DEPRESSION; FEMALE; HAMILTON SCALE; HORMONAL THERAPY; HUMAN; MOOD; POSTMENOPAUSE; PRIORITY JOURNAL; AFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; TIME; WOMEN'S HEALTH;

AFFECT; DEPRESSION; ESTROGEN ANTAGONISTS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE; MIDDLE AGED; POSTMENOPAUSE; PSYCHIATRIC STATUS RATING SCALES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS; WOMEN'S HEALTH;

EID: 3542996275     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Grigoriadis S, Kennedy SH: Role of estrogen in the treatment of depression. Am J Ther 9:503-509, 2002.
2. Carranza-Lira S, Valentino-Figueroa ML: Estrogen therapy for depression in postmenopausal women. Int J Gynecol Obstet 65:35-38, 1999.
3. Girdler SS, O'Briant C, Steege J, et al: A comparison of the effect of estrogen with or without progesterone on mood and physical symptoms in postmenopausal women. J Womens Health Gend Based Med 8:637-646, 1999.
4. Hammarback S, Backstrom T, Holst J, et al: Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy. Acta Obstet Gynecol Scand 64:393-397, 1985.
5. Sherwin BB: The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 72:336-343, 1991.
6. Bjorn I, Sundstrom-Poromaa I, Bixo M, et al: Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocrinol Metab 88:2026-2030, 2003.
7. Nickelsen T, Lufkin EG, Riggs BL, et al: Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. Psychoneuroendocrinology 24:115-128, 1999.
8. Jarkova NB, Martenyi F, Masanauskaite D, et al: Mood effect of raloxifene in postmenopausal women. Maturitas 42:71-75, 2002.
9. Shepherd JE: Effects of estrogen on cognition mood, and degenerative brain diseases. J Am Pharm Assoc 41:221-228, 2001.
10. Schmidt PJ, Neieman L, Danaceau MA, et al: Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 183:414-420, 2000.
11. Halbreich U, Kahn LS: Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 15:797-817, 2001.
12. Archer JS: NAMS/Solvay Resident Essay Award: Relationship between estrogen, serotonin, and depression. Menopause 6:71-78, 1999.
13. Whooley MA, Grady D, Cauley JA: Postmenopausal estrogen therapy and depressive symptoms in older women. J Gen Intern Med 15:535-541, 2000.
14. Joffe H, Cohen LS: Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge? Biol Psychiatry 44:798-811, 1998.
15. Fink G, Sumner BE, Rosie R, et al: Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol 16:325-344, 1996.
16. Klaiber EL, Broverman DM, Vogel W, et al: Effects of estrogen therapy on plasma MAO activity and EEG driving responses of depressed women. Am J Psychiatry 128:1492-1498, 1972.
17. López-Jaramillo P, Teran E: Improvement in functions of central nervous system by estrogen replacement therapy might be related with an increased nitric oxide production. Endothelium 6:263-266, 1999.
18. Hlatky MA, Boothroyd D, Vittinghoff E, et al: Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 287:591-597, 2002.
19. Hays J, Ockene JK, Brunner RL, et al: Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348:1839-1854, 2003.